A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function

Hyun Yang; Hyun Young Woo; Soon Kyu Lee; Ji Won Han; Bohyun Jang; Hee Chul Nam; Hae Lim Lee; Sung Won Lee; Do Seon Song; Myeong Jun Song; Jung Suk Oh; Ho Jong Chun; Jeong Won Jang; Angelo Lozada; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon

doi:10.3350/cmh.2016.0071

A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function

Hyun Yang
, Hyun Young Woo
, Soon Kyu Lee
, Ji Won Han
, Bohyun Jang
, Hee Chul Nam
, Hae Lim Lee
, Sung Won Lee
, Do Seon Song
, Myeong Jun Song
, Jung Suk Oh
, Ho Jong Chun
, Jeong Won Jang
, Angelo Lozada
, Si Hyun Bae
, Jong Young Choi
, Seung Kew Yoon

Makati Medical Center

Research output: Contribution to journal › Article › peer-review

30 Scopus citations

Abstract

BACKGROUND/AIMS: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).

METHODS: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.

RESULTS: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).

CONCLUSIONS: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.

Original language	English
Pages (from-to)	128-137
Number of pages	10
Journal	Clinical and Molecular Hepatology
Volume	23
Issue number	2
DOIs	https://doi.org/10.3350/cmh.2016.0071
State	Published - 1 Jun 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Administration, Metronomic
Carcinoma, Hepatocellular
Portal vein
Sorafenib
Thrombosis

Access to Document

10.3350/cmh.2016.0071

Cite this

Yang, H., Woo, H. Y., Lee, S. K., Han, J. W., Jang, B., Nam, H. C., Lee, H. L., Lee, S. W., Song, D. S., Song, M. J., Oh, J. S., Chun, H. J., Jang, J. W., Lozada, A., Bae, S. H., Choi, J. Y., & Yoon, S. K. (2017). A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clinical and Molecular Hepatology, 23(2), 128-137. https://doi.org/10.3350/cmh.2016.0071

@article{7368427087ae4bbd92e2d5b95a035c8b,

title = "A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function",

abstract = "BACKGROUND/AIMS: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).METHODS: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.RESULTS: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).CONCLUSIONS: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.",

keywords = "Administration, Metronomic, Carcinoma, Hepatocellular, Portal vein, Sorafenib, Thrombosis",

author = "Hyun Yang and Woo, \{Hyun Young\} and Lee, \{Soon Kyu\} and Han, \{Ji Won\} and Bohyun Jang and Nam, \{Hee Chul\} and Lee, \{Hae Lim\} and Lee, \{Sung Won\} and Song, \{Do Seon\} and Song, \{Myeong Jun\} and Oh, \{Jung Suk\} and Chun, \{Ho Jong\} and Jang, \{Jeong Won\} and Angelo Lozada and Bae, \{Si Hyun\} and Choi, \{Jong Young\} and Yoon, \{Seung Kew\}",

year = "2017",

month = jun,

day = "1",

doi = "10.3350/cmh.2016.0071",

language = "English",

volume = "23",

pages = "128--137",

journal = "Clinical and Molecular Hepatology",

issn = "2287-2728",

publisher = "Korean Association for the Study of the Liver",

number = "2",

}

Yang, H, Woo, HY, Lee, SK , Han, JW, Jang, B, Nam, HC, Lee, HL, Lee, SW , Song, DS , Song, MJ , Oh, JS , Chun, HJ , Jang, JW, Lozada, A, Bae, SH, Choi, JY & Yoon, SK 2017, 'A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function', Clinical and Molecular Hepatology, vol. 23, no. 2, pp. 128-137. https://doi.org/10.3350/cmh.2016.0071

TY - JOUR

T1 - A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function

AU - Yang, Hyun

AU - Woo, Hyun Young

AU - Lee, Soon Kyu

AU - Han, Ji Won

AU - Jang, Bohyun

AU - Nam, Hee Chul

AU - Lee, Hae Lim

AU - Lee, Sung Won

AU - Song, Do Seon

AU - Song, Myeong Jun

AU - Oh, Jung Suk

AU - Chun, Ho Jong

AU - Jang, Jeong Won

AU - Lozada, Angelo

AU - Bae, Si Hyun

AU - Choi, Jong Young

AU - Yoon, Seung Kew

PY - 2017/6/1

Y1 - 2017/6/1

N2 - BACKGROUND/AIMS: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).METHODS: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.RESULTS: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).CONCLUSIONS: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.

AB - BACKGROUND/AIMS: Metronomic chemotherapy (MET) is frequently administered in comparatively low doses as a continuous chemotherapeutic agent. The aim of this study was to evaluate the feasibility and overall survival (OS) of MET compared to sorafenib for advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).METHODS: A total of 54 patients with advanced HCC and PVTT who had undergone MET were analyzed between 2005 and 2013. A total of 53 patients who had undergone sorafenib therapy were analyzed as the control group. The primary endpoint of this study was OS.RESULTS: The median number of MET cycles was two (1-15). The OS values for the MET group and sorafenib group were 158 days (132-184) and 117 days (92-142), respectively (P=0.029). The Cox proportional-hazard model showed that a higher risk of death was correlated with higher serum alpha fetoprotein level (≥400 mg/dL, hazard ratio [HR]=1.680, P=0.014) and Child-Pugh class B (HR=1.856, P=0.008).CONCLUSIONS: MET was associated with more favorable outcomes in terms of overall survival than was sorafenib in patients with advanced HCC with PVTT, especially in patients with poor liver function. Therefore, MET can be considered as a treatment option in patients with advanced HCC with PVTT and poor liver function.

KW - Administration, Metronomic

KW - Carcinoma, Hepatocellular

KW - Portal vein

KW - Sorafenib

KW - Thrombosis

UR - https://www.scopus.com/pages/publications/85050577808

U2 - 10.3350/cmh.2016.0071

DO - 10.3350/cmh.2016.0071

M3 - Article

C2 - 28494528

AN - SCOPUS:85050577808

SN - 2287-2728

VL - 23

SP - 128

EP - 137

JO - Clinical and Molecular Hepatology

JF - Clinical and Molecular Hepatology

IS - 2

ER -

A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this